knowledge -WSS

knowledge

author：hotspot 2025-09-30 17:11:04 - browse：169

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

focus

hotspot

WSS

Brain technologies pose threats that are all too real, experts warn

Primary care doctor shortage won't be solved by free med school tuition

PBM reform efforts get punted in Congress

Novel spinal cord stimulator treats paralysis without surgery

Alabama frozen embryo ruling has major implications for IVF clinics

BIO to announce reorganization, senior leaders expected to depart

explore

knowledge

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Antivenom research: Lessons from HIV applied in search for universal antidote

In Memoriam: Notable people who died in 2023

Warren pushes Witty on UnitedHealth's control over physicians

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Deliver public health messages at the right time

Novavax promises a turnaround & Lilly roils the obesity market

In utero gene editing: an explainer

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

With competition flaring, obesity drug hits goal in liver disease study

hotspot

Black vets could get higher VA benefits if race not used in lung test

Ed Silverman on new gene therapies, biosimilars, coffee, and more

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

Alabama frozen embryo ruling has major implications for IVF clinics

Community Health Systems hospitals under DOJ investigation

The creative science of coining drug names

focus

focus

hotspot

hotspot